Erratum: "Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation" (Hepatology (2009) (49) (471-481) 10.1002/hep.22652);Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation

Hepatology

Volumn 49, Issue 2, 2009, Pages 471-481

  Ney, Jasmin T ^a   Schmidt, Thomas ^a   Kurts, Christian ^a   Zhou, Qi ^a,b   Eckert, Dawid ^a   Felsher, Dean W ^c   Schorle, Hubert ^a   Knolle, Percy ^a   Tüting, Thomas ^a   Barchet, Winfried ^a   Büttner, Reinhard ^a   Limmer, Andreas ^a   Gütgemann, Ines ^a  

^a UNIVERSITY OF BONN   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYL CPG BINDING PROTEIN; MYC PROTEIN; OVALBUMIN; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; PRIMER DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; LIVER CARCINOMA; LIVER TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MODEL; ADOPTIVE TRANSFER; ANIMAL; ANTIGEN PRESENTING CELL; CROSS BREEDING; DISEASE MODEL; FLOW CYTOMETRY; GENETICS; GENOTYPE; HUMAN; IMMUNOLOGY; MORTALITY; ONCOGENE MYC; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN-PRESENTING CELLS; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; DNA PRIMERS; FLOW CYTOMETRY; GENES, MYC; GENOTYPE; HUMANS; LIVER NEOPLASMS; MICE; MICE, TRANSGENIC; OVALBUMIN; RECEPTORS, ANTIGEN, T-CELL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 61949175146     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22886     Document Type: Erratum

References (42)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2:533-543.
2. Greten TF, Manns MP, Korangy F. Immunotherapy of HCC. Rev Recent Clin Trials 2008;3:31-39.
3. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: A novel perspective. Cancer Res 2007;67: 1883-1886.
4. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/ regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-18543.
5. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-1691.
6. Knolle PA, Limmer A. Neighborhood politics: The immunoregulatory function of organ-resident liver endothelial cells. Trends Immunol 2001; 22:432-437.
7. Limmer A, Knolle PA. Liver sinusoidal endothelial cells: A new type of organ-resident antigen-presenting cell. Arch Immunol Ther Exp (Warsz) 2001;49(Suppl 1):S7-S11.
8. Kurts C, Kosaka H, Carbone FR, Miller JF, Heath WR. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med 1997;186:239-245.
9. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005;437:141-146.
10. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-907.
11. Baron U, Freundlieb S, Gossen M, Bujard H. Co-regulation of two gene activities by tetracycline via a bidirectional promoter. Nucleic Acids Res 1995;23:3605-3606.
12. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999;4:199-207.
13. Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lubbert H, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A 1996;93:10933-10938.
14. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:1112-1117.
15. Woo J, Lu L, Rao AS, Li Y, Subbotin V, Starzl TE, et al. Isolation, phenotype, and allostimulatory activity of mouse liver dendritic cells. Transplantation 1994;58:484-491.
16. Coles RM, Mueller SN, Heath WR, Carbone FR, Brooks AG. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J Immunol 2002;168:834-838.
17. Berg M, Wingender G, Djandji D, Hegenbarth S, Momburg F, Hammerling G, et al. Cross-presentation of antigens from apoptotic tumor cells by liver sinusoidal endothelial cells leads to tumor-specific CD8+ T cell tolerance. Eur J Immunol 2006;36:2960-2970.
18. Beer S, Zetterberg A, Ihrie RA, McTaggart RA, Yang Q, Bradon N, et al. Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol 2004;2:e332.
19. Gutgemann I, Fahrer AM, Altman JD, Davis MM, Chien YH. Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen. Immunity 1998;8:667-673.
20. Pardoll D. T cells and tumours. Nature 2001;411:1010-1012.
21. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25: 267-296.
22. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants. Eur J Immunol 1997;27:2340-2344.
23. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996;8:271-280.
24. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-148.
25. Derkow K, Loddenkemper C, Mintern J, Kruse N, Klugewitz K, Berg T, et al. Differential priming of CD8 and CD4 T-cells in animal models of autoimmune hepatitis and cholangitis. HEPATOLOGY 2007;46:1155-1165.
26. Sprengers D, Sille FC, Derkow K, Besra GS, Janssen HL, Schott E, et al. Critical role for CD1d-restricted invariant NKT cells in stimulating intrahepatic CD8 T-cell responses to liver antigen. Gastroenterology 2008;134: 2132-2143.
27. Savage PA, Vosseller K, Kang C, Larimore K, Riedel E, Wojnoonski K, et al. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 2008;319:215-220.
28. Worschech A, Kmieciak M, Knutson KL, Bear HD, Szalay AA, Wang E, et al. Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res 2008;68:2436-2446.
29. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999;18:3004-3016.
30. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001;7:297-303.
31. van Stipdonk MJ, Hardenberg G, Bijker MS, Lemmens EE, Droin NM, Green DR, et al. Dynamic programming of CD8+ T lymphocyte responses. Nat Immunol 2003;4:361-365.
32. Ferber I, Schonrich G, Schenkel J, Mellor AL, Hammerling GJ, Arnold B. Levels of peripheral T cell tolerance induced by different doses of tolerogen. Science 1994;263:674-676.
33. Benson JM, Campbell KA, Guan Z, Gienapp IE, Stuckman SS, Forsthuber T, et al. T-cell activation and receptor downmodulation precede deletion induced by mucosally administered antigen. J Clin Invest 2000;106: 1031-1038.
34. Limmer A, Ohl J, Kurts C, Ljunggren HG, Reiss Y, Groettrup M, et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med 2000; 6:1348-1354.
35. Holz LE, Benseler V, Bowen DG, Bouillet P, Strasser A, O'Reilly L, et al. Intrahepatic murine CD8 T cell activation associates with a distinct phenotype leading to Bim-dependent death. Gastroenterology 2008;135:989-997.
36. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-685.
37. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81.
38. Bukowski RM, Rayman P, Uzzo R, Bloom T, Sandstrom K, Peereboom D, et al. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: Clinical relevance and effects of cytokine therapy. Clin Cancer Res 1998;4:2337-2347.
39. Whiteside TL. Down-regulation of zeta-chain expression in T cells: A biomarker of prognosis in cancer? Cancer Immunol Immunother 2004;53: 865-878.
40. Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 2005;11:1010-1020.
41. Weinhold M, Sommermeyer D, Uckert W, Blankenstein T. Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity. J Immunol 2007;179:5534-5542.
42. Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 2007;204:49-55.